IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Kamau Therapeutics
Company Type: Therapeutic development
Main focus: Developing curative stem-cell therapies for genetic diseases
Company stage: Clinical
Diseases: Sickle cell disease
Genome-editing tool: CRISPR-Cas9
Funding stage: Early Venture Capital
Location: South San Francisco, California, USA
Website: https://kamautx.com/
Pipeline:
Partners:
Kamau Therapeutics is a clinical-stage, next-generation gene correction company that aims to develop curative treatments for a range of genetic diseases. The company’s platform technology is based on the pioneering research of company co-founder Dr. Matthew Porteus, MD, PhD, and offers broad potential for transforming human health. Kamau’s lead clinical programme, nulabeglogene autogedtemcel (nula-cel), previously developed by Graphite Bio, is the only haematopoietic stem-cell based therapy in clinical development for sickle cell disease that precisely corrects the mutation in the beta-globin gene found in the sickled haemoglobin of SCD patients, restoring patient’s stem cells to normal adult haemoglobin.
